A Phase 4 interventional study of liraglutide and sitagliptin in Diabetes and Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S. Completed at 25 sites in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2017-03-09.
Sponsored by Novo Nordisk A/S · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 151 studies testing liraglutide in Diabetes Mellitus, Type 2 — 6 open to participants now, 7 under way, 1 of them phase 3. Liraglutide · Diabetes Mellitus, Type 2.
Among the 151 studies testing liraglutide in Diabetes Mellitus, Type 2, this one is the 31st largest by enrollment, is one of 18 that started in 2013, is one of 48 in phase 4, and was the 88th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →6 of the 151 studies testing liraglutide in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:
Mayo Clinic · Sites in United States
Ages 25–70
Mansa · Sites in United States
Ages 10+
Biolingus · Sites in Hong Kong
Ages 18–65
RenJi Hospital · Sites in China
Ages 18–65
University of Virginia · Sites in United States
Ages 21–60 · Healthy volunteers
By country, each count listing its studies:
Liraglutide: first FDA approval 2010 (VICTOZA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →
Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
151 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 27 · Phase 2 21 · Phase 3 46 · Phase 4 48
First in 1999; this study’s year is marked. 18 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 368 is above the median of 80 across 8,359 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 62 across the 151 interventional studies. Of the 127 that completed or were terminated, 52 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
75 of 151 have an industry lead sponsor. The 10 most frequent:
Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
643 studies in Diabetes Mellitus, Type 2 by Novo Nordisk A/S: 25 open now, 29 under way, 11 of them phase 3. Of 603 finished, 174 (29%) have results posted.
Among the 643 studies in Diabetes Mellitus, Type 2 by Novo Nordisk A/S, this one is the 148th largest by enrollment of the 428 interventional ones that give a count, is one of 33 that started in 2013, is one of 75 in phase 4, and was the 366th registered.
Novo Nordisk A/S’s Diabetes Mellitus, Type 2 studies by the year they started, since 1997.
1 of the studies testing liraglutide in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03883412University of VirginiaEffect of Exercise and/or Liraglutide on Vascular Dysfunction and Insulin Sensitivity in Type 2 Diabetes ( ZQL007) | 2027-06 |
Add it to your calendar (.ics) → With an account.
Among the 151 studies testing liraglutide in Diabetes Mellitus, Type 2, from their registry updates:
Among Novo Nordisk A/S’s 643 in Diabetes Mellitus, Type 2:
This tab as a report to print or save as PDF → With an account.
This trial is conducted in Asia. The aim of this trial is to investigate the efficacy and safety of liraglutide compared to sitagliptin, both as add-on to metformin in Chinese subjects with type 2 diabetes inadequately controlled on metformin monotherapy. Eligible subjects will continue their metformin background treatment during the trial.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
This study's enrollment of 368 is above the median of 80 across 8,359 interventional studies indexed under Diabetes Mellitus, Type 2.
Browse Diabetes Mellitus, Type 2 studies →Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
Compared within Diabetes Mellitus, Type 2, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
2-week screening period, 26-week treatment duration, and a 1-week follow-up period
Drug: liraglutide
2-week screening period, 26-week treatment duration, and a 1-week follow-up period
Drug: sitagliptin
Administered subcutaneously (s.c., under the skin) once daily as add-on to the subject's stable pre-trial metformin dose.
Administered orally once daily as add-on to the subject's stable pre-trial metformin dose.
Change From Baseline in Glycosylated Haemoglobin (HbA1c)
Mean change from baseline in glycosylated haemoglobin A1c (HbA1c) at Week 26.
Time frame: Week 0, week 26
Change From Baseline in Fasting Plasma Glucose
Mean change from baseline in fasting plasma glucose (FPG) at Week 26.
Time frame: Week 0, week 26
Change From Baseline in 7-point Self-measured Plasma Glucose Profile
Mean change from baseline in mean of 7-point self-measured plasma glucose at week 26. The 7-point self-measured plasma glucose levels were measured before and after (120 minutes after the start of the meal) the three main meals (breakfast, lunch and dinner), and at bed time.
Time frame: Week 0, week 26
Subjects Who Achieve (Yes/no) HbA1c Below 7.0 % (American Diabetes Association Target)
Calculated as the percentage of subjects achieving treatment target of HbA1c \< 7.0% at Week 26
Time frame: After 26 weeks of treatment
Subjects Who Achieve (Yes/no) HbA1c Below or Equal to 6.5 % (American Association of Clinical Endocrinologists Target)
Calculated as the percentage of subjects achieving treatment target of HbA1c \<= 6.5% at Week 26
Time frame: After 26 weeks of treatment
Number of Confirmed Hypoglycaemic Episodes
confirmed hypoglycaemic episode defined as severe (unable to treat her/himself) or biochemically confirmed by a plasma glucose \< 3.1 mmol/L
Time frame: Weeks 0-26
This trial was conducted at 25 sites in China.
| Milestone | Liraglutide | Sitagliptin |
|---|---|---|
| Started | 184 | 184 |
| Exposed | 183 | 184 |
| Completed | 157 | 170 |
| Not completed | 27 | 14 |
Mean change from baseline in glycosylated haemoglobin A1c (HbA1c) at Week 26.
| Percent (%) glycosylated haemoglobin | Liraglutide | Sitagliptin |
|---|---|---|
| Change From Baseline in Glycosylated Haemoglobin (HbA1c) | -1.666 ± 0.9982 | -0.969 ± 0.9742 |
Mean change from baseline in fasting plasma glucose (FPG) at Week 26.
| mmol/L | Liraglutide | Sitagliptin |
|---|---|---|
| Change From Baseline in Fasting Plasma Glucose | -2.347 ± 2.1655 | -1.205 ± 2.2961 |
Mean change from baseline in mean of 7-point self-measured plasma glucose at week 26. The 7-point self-measured plasma glucose levels were measured before and after (120 minutes after the start of the meal) the three main meals (breakfast, lunch and dinner), and at bed time.
| mmol/L | Liraglutide | Sitagliptin |
|---|---|---|
| Change From Baseline in 7-point Self-measured Plasma Glucose Profile | -2.25 ± 2.244 | -1.36 ± 2.204 |
Calculated as the percentage of subjects achieving treatment target of HbA1c \< 7.0% at Week 26
| percentage of subjects | Liraglutide | Sitagliptin |
|---|---|---|
| Subjects Who Achieve (Yes/no) HbA1c Below 7.0 % (American Diabetes Association Target) | 76.5 | 52.6 |
Calculated as the percentage of subjects achieving treatment target of HbA1c \<= 6.5% at Week 26
| percentage of subjects | Liraglutide | Sitagliptin |
|---|---|---|
| Subjects Who Achieve (Yes/no) HbA1c Below or Equal to 6.5 % (American Association of Clinical Endocrinologists Target) | 61.7 | 26.3 |
confirmed hypoglycaemic episode defined as severe (unable to treat her/himself) or biochemically confirmed by a plasma glucose \< 3.1 mmol/L
| episodes | Liraglutide | Sitagliptin |
|---|---|---|
| Number of Confirmed Hypoglycaemic Episodes | 2 | 1 |
Collected over Weeks 0-26. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Liraglutide | — | 3/183 (1.6%) | 65/183 (35.5%) |
| Sitagliptin | — | 6/184 (3.3%) | 14/184 (7.6%) |
| Event | Liraglutide | Sitagliptin |
|---|---|---|
| Sudden hearing lossEar and labyrinth disorders | 1/183 | 0/184 |
| BronchitisInfections and infestations | 1/183 | 0/184 |
| Diabetic ketoacidosisMetabolism and nutrition disorders | 1/183 | 0/184 |
| Gastric ulcerGastrointestinal disorders | 0/183 | 1/184 |
| HaemorrhoidsGastrointestinal disorders | 0/183 | 1/184 |
| Thyroid cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/183 | 1/184 |
| Thymoma malignantNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/183 | 1/184 |
| Atrial fibrillationCardiac disorders | 0/183 | 1/184 |
| Cerebral infarctionNervous system disorders | 0/183 | 1/184 |
| Event | Liraglutide | Sitagliptin |
|---|---|---|
| NauseaGastrointestinal disorders | 27/183 | 1/184 |
| Decreased appetiteMetabolism and nutrition disorders | 20/183 | 1/184 |
| DiarrhoeaGastrointestinal disorders | 15/183 | 4/184 |
| Lipase increasedInvestigations | 11/183 | 8/184 |
Safety analysis set included all subjects receiving at least one dose of investigational product.
| Age, Continuous(years) | Liraglutide | Sitagliptin | Total |
|---|---|---|---|
| Mean | 51.7 ± 10.7 | 51.4 ± 11.0 | 51.5 ± 10.9 |
| Sex: Female, Male(Participants) | Liraglutide | Sitagliptin | Total |
|---|---|---|---|
| Female | 81 | 67 | 148 |
| Male | 102 | 117 | 219 |
| Body mass index (BMI)(kg/m^2) | Liraglutide | Sitagliptin | Total |
|---|---|---|---|
| Mean | 27.32 ± 3.389 | 27.16 ± 4.029 | 27.24 ± 3.720 |
| Body weight(kg) | Liraglutide | Sitagliptin | Total |
|---|---|---|---|
| Mean | 76.17 ± 13.562 | 75.78 ± 15.089 | 75.98 ± 14.330 |
| Duration of diabetes(years) | Liraglutide | Sitagliptin | Total |
|---|---|---|---|
| Mean | 5.31 ± 4.39 | 5.22 ± 5.40 | 5.27 ± 4.92 |
| Fasting plasma glucose (FPG)(mmol/L) | Liraglutide | Sitagliptin | Total |
|---|---|---|---|
| Mean | 9.26 ± 2.216 | 9.46 ± 2.237 | 9.36 ± 2.226 |
| Glycosylated haemoglobin A1c (HbA1c)(Percent (%) glycosylated haemoglobin) | Liraglutide | Sitagliptin | Total |
|---|---|---|---|
| Mean | 8.14 ± 0.833 | 8.11 ± 0.780 | 8.12 ± 0.806 |
The record gives a start of Dec 2013, a primary completion of Nov 2014 and a completion of Nov 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2015, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Liraglutide